A broad product portfolio suited for many indications
At Galecto, we are developing a range of molecules that target different members of the galectin family. Our deep insight into Galectin biology and chemistry has enabled us to build an expanding portfolio of both activators and inhibitors with differing specificities and routes of delivery.
Galecto Biotech’s Lead Molecule TD139 is Safe, & Well Tolerated, with Strong Evidence of Target Engagement and Effects on Disease Biomarkers in a Phase Ib/IIa trial in Patients with IPF
March 10, 2017
Today, Galecto Biotech AB can announce the successful completion of its phase Ib/IIa clinical trial of inhaled TD139. This novel drug, targeting Galectin-3, demonstrates ground-breaking results for patients suffering from Idiopathic Pulmonary Fibrosis (IPF), a usually fatal disease characterised by a progressive decline in lung function.
Successful trial shows unprecedented results
Galecto Biotech has successfully completed its phase Ib/IIa clinical trial of TD139, the biotech company’s new drug developed for patients suffering from Idiopathic Pulmonary Fibrosis.
Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research into galectins and galectin modulators, which combined with a strong patent estate gives Galecto a unique platform.
Tel: (+45) 70 70 52 10 – Email: info@galecto.com